Labcorp Holdings Inc Stock Price, News & Analysis

Praia Health, Providence, and Labcorp (LH) announced a collaboration that connected Praia Health’s patient experience platform with Labcorp’s scheduling and lab-ordering systems to streamline lab booking and patient workflows.

Key outcomes include an 8-fold increase in scheduled appointments, a 52% increase in lab bookings via digital notifications, 52% higher patient bill-pay engagement, 37% of canceled appointments rebooked within 30 days, and 23% of appointments self-modified or canceled via the app—reducing no-shows. The partners report improved patient engagement, operational efficiency, and plans to explore genomics, chronic care, at-home collection, and clinical trial recruitment.

Labcorp (NYSE: LH) announced that its Board declared a quarterly cash dividend of $0.72 per share. The dividend is payable on December 11, 2025 to shareholders of record at the close of business on November 26, 2025.

Labcorp (NYSE: LH) has announced a strategic collaboration with Roche to implement FDA-cleared VENTANA® DP 600 and DP 200 slide scanners for digital pathology. This initiative aims to transform traditional pathology by converting glass slides into high-resolution digital images, enabling remote viewing and analysis.

The collaboration comes as the U.S. faces a projected shortage of 5,700 pathologists by 2030. The digital pathology system will enhance diagnostic capabilities through improved access to expertise, streamlined workflows, and future AI integration. This builds upon Labcorp's existing relationship with Roche and extends across their Diagnostics and Biopharma Laboratory Services segments.

Labcorp (NYSE:LH), a leading global laboratory services provider, has scheduled its third quarter 2025 financial results announcement for Tuesday, October 28, 2025, before market opening.

The company will host a conference call and webcast at 9:00 AM ET to discuss the results. Investors can access the webcast through Labcorp's Investor Relations website or register for dial-in access. A replay will be available for approximately one year, until October 15, 2026.

Labcorp (NYSE: LH) has completed the acquisition of select oncology and clinical testing assets from BioReference Health, a subsidiary of OPKO Health (Nasdaq: OPK). The transaction is valued at up to $225 million, comprising $192.5 million paid at closing and a potential $32.5 million performance-based earnout.

The acquisition strengthens Labcorp's oncology testing portfolio and expands its diagnostic capabilities. BioReference Health will retain its core clinical testing operations in NY/NJ and its 4Kscore® Test franchise, which generated approximately $300 million in revenue for 2024. OPKO plans to use part of the proceeds to fund its expanded share repurchase program.

Labcorp (NYSE: LH), a leading provider of innovative laboratory services, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's executive management team will engage in a fireside chat on Tuesday, September 9, at 7:45 am ET.

Investors and interested parties can access a live audio webcast of the presentation through Labcorp's investor relations website at ir.Labcorp.com. The presentation will also be archived for future replay.

Labcorp (NYSE:LH) has launched the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test for Alzheimer's disease diagnosis. This groundbreaking test demonstrates 92% positive predictive value and 97% negative predictive value in clinical studies.

The blood-based diagnostic test provides comparable results to traditional methods like CSF testing and PET scans, but through a simpler, more affordable, and less invasive blood draw. Available nationwide through Labcorp's 2,200+ Patient Service Centers, the test is designed for adults 50 and older showing cognitive decline symptoms in specialized care settings.

Labcorp (NYSE: LH) has launched Test Finder, a pioneering generative AI tool developed in collaboration with Amazon Web Services (AWS). The tool aims to streamline laboratory test selection for healthcare providers by allowing them to input queries in plain language and receive curated test recommendations.

Test Finder, built using Amazon Bedrock and large language model technology, provides access to thousands of lab tests across multiple therapeutic areas. The tool addresses a significant healthcare challenge, as laboratory testing influences nearly 70% of clinical decisions, while physicians spend over three hours daily on documentation and test ordering. According to an AMA survey, 57% of physicians view administrative automation through AI as healthcare's greatest AI opportunity.

Labcorp (NYSE: LH) has achieved IVDR CE-marking for its PGDx elio tissue complete test in the European Union, making it the first and only test of its kind approved for comprehensive solid tumor profiling under new EU regulations. The test, which already has FDA clearance in the US, will help diagnose and treat approximately 2.7 million people diagnosed with cancer annually in the EU.

The in vitro diagnostic assay can analyze multiple biomarkers simultaneously, even with limited tissue samples, enabling faster and more effective patient management plans. The test will be available through Labcorp's central laboratory in Geneva, Switzerland, supporting both biopharma partners and investigational use in global clinical trials.